Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement
FRAMINGHAM, MA / ACCESSWIRE /
May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ( Xenetic or the Company ), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the first quarter of 2021 and provided a corporate update. During the first quarter our focus remained on advancing the development of our XCART platform, which we believe has the potential to provide a personalized CAR T therapy targeting cancers with a patient-and tumor-specific approach. The commencement of our exploratory patient biopsy trial is a key component of our preclinical development strategy and an important step forward toward advancing into a Phase 1 study, com